Comunicati.net - Comunicati pubblicati - Coherent Market Insights Comunicati.net - Comunicati pubblicati - Coherent Market Insights Sun, 21 Apr 2019 12:32:34 +0200 Zend_Feed_Writer 1.12.20 (http://framework.zend.com) http://comunicati.net/utenti/24662/1 Organ Preservation Market: Latest Advancements & Market Outlook 2018 to 2026 Sat, 20 Apr 2019 11:58:44 +0200 http://comunicati.net/comunicati/aziende/varie/543951.html http://comunicati.net/comunicati/aziende/varie/543951.html Coherent Market Insights Coherent Market Insights Organ preservation involves removal of organs from the bodies, which are then stored for transplantation. Organ preservation systems are exclusively prepared and maintained according to the biological environment (temperature and oxygen) needed to store particular organs. Different body organs require specific and suitable storage conditions to maintain their anatomical and physiological processes. Important parameters in organ preservation include delivering of high quality organs to the donors, matching the patient and organ suitability, and restart of life of the organs and sustaining functions after the transplantation. Organ transplantation process starts with removing the needed organ from the donor body, then the organ is stored and transported. The conditions of the organs are maintained in its natural state and functioning by avoiding any significant damage. Organ is preserved thoroughly till it is transplanted into the patient’s body. The most suitable temperature for preservation is between 4°C to 8°C, which significantly reduces the metabolic rate of the organ. Click To Read More On Organ Preservation Market.

Organ transplantation procedure has evolved with increased procedural feasibility and better understanding of immunity system and reasons behind organ rejection has allowed for improved matching rates for organs and patients after transplants. Enhancement in surgical techniques along with networking of organ donor has saved many lives, owing to improvement of transplantation procedures.

Increasing demand for organ transplants is expected to fuel growth of organ preservation market

According to Organ Procurement and Transplantation Network (OPTN), in 2017, over 117,000 people are in the waiting list of national organ transplant and only around 17,155 organs are transplanted in the year.

Moreover, according to National Kidney Foundation, in 2016, around 121,678 people are waiting for lifesaving organ transplants in the U.S., among which, around 100,791 people are waiting for kidney transplants.

Moreover, many innovative techniques are promising such as normo, sub-normo and hypothermic perfusion technologies, hypothermic surgery and gas persufflation. Furthermore, potential organ preservation techniques such as Organ Bioengineering and Organ Banking are unique and scalable opportunities.

Advancement in technology and enhancement in techniques are expected to fuel growth of the organ preservation market

Tissue preservation is getting easier due to rapid advancement in technology and can greatly effect by improved matching of donor organ and receiver with reduced organ rejection rates, limiting organ discard, increasing donor utilization, reducing costs such associated with short-notice plane and helicopter transportation. Adult-derived stem cells such as mesenchymal stem cells (MSCs) offer great therapeutic promise for numerous clinical applications. MSCs can be taken from any tissue in the body that is capable of healing bone marrow, dental pulp, blood, adipose, liver, brain, pancreas, and placenta.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1072

Key players in the organ preservation market

Key players operating in the global organ preservation market include Teva Pharmaceutical Industries Ltd., Dr. Franz Köhler Chemie GmbH, BioLife Solutions, XVIVO Perfusion AB, Bristol-Myers Squibb, Inc., and ToleroTech, Inc., Lifeline Scientific, Preservation Solutions Inc., and Claris Injectables Limited. Moreover, in 2015, Dr. Franz Köhler Chemie GmbH, opened a new manufacturing site for Custodiol, the market leading organ protective solution of the company.

Regional growth engines of organ preservation market

Regional segmentation of the organ preservation market by Coherent Market Insights comprises, North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America market is expected to hold a dominant position in the global organ preservation market. This is mainly due of better organ preservation facilities, research and development, and skilled professionals in the region. Moreover, increasing geriatric population, as they are more prone to chronic diseases, further augments growth of the market. Asia Pacific region is expected to witness highest growth rate in the market, owing to increasing customer base, increasing organ donation awareness, and increasing healthcare expenditure. Furthermore, low cost and availability of technology, increasing transplant surgeries, and increasing organ donation awareness are the few factors fueling growth of the market in the region.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Life Cell Imaging Market is Anticipated to Show Growth by 2026 Sat, 20 Apr 2019 09:24:17 +0200 http://comunicati.net/comunicati/aziende/varie/543899.html http://comunicati.net/comunicati/aziende/varie/543899.html Coherent Market Insights Coherent Market Insights The Global Life Cell Imaging Market was valued at US$ 4.4 billion in 2016 and is expected to witness a robust CAGR of 8.60% over the forecast period (2017 - 2025).

The global life cell imaging industry has observed a notable growth over the last few decades due to significant increase in the demand for life cell imaging techniques for the study of cancer, neuroscience and drug discovery. Cellular imaging involves use of techniques that enable the detection and analysis of cellular organelles and macromolecules through light- or electron-based microscopes. Cell imaging is rapidly evolving as new technologies are being introduced such as light sheet microscopy, intra-vital microscopy, environmental scanning electron microscopy and high throughput microscopy. Furthermore, life cell imaging use fluorophore labeled molecules, fluorescent dyes and recombinant plasmid systems for imaging expression, transport, co-localization and degradation in either living or fixed cells. In addition, cellular structures and functions can be visually detected using methods such as wide field fluorescence and fluorescence resonance energy transfer (FRET) microscopy.

Market Dynamics

The life cell imaging market is gaining significant traction due to rising adoption of techniques in various fields such as stem cell biology, neurobiology, developmental biology, cell biology, and oncology, drug discovery, and electro physiology. Furthermore, life cell imaging has emerged as a potential tool that helps provide insights into dynamic processes in living cells and cell function with the help of agents such as green fluorescent protein (GFP) and multicolored probes that precisely label molecules and directly probe its function in live cells by light microscopy. Due to the visualization ability of the imaging tools, the dynamics of protein vesicles, organelles, cells and tissue has provided new insights into how cells function. However, the factors such as shortage of skilled professionals and high cost of the advanced microscopes hinder market growth to a certain extent.

Cellular imaging refers to the techniques that allows the detection and analysis of various cellular organelles and macromolecules using a light-based or electron based microscopes. These are then mainly analyzed through computer based programs. Apart from the structural organization and orientation of organs and cells in organisms, dynamic processes contributes a major part in understanding the function and mechanism of a biological entity. Live life cell imaging refers to the non-invasive techniques such as optical methods that help visualize functional behavior of the cells with the help of high-end imaging instruments such as stereo microscopes. The high-content screening systems have become a popular analytical tool for elucidation of biological mechanisms as well as for the study of dynamic functions of the cells. The life cell imaging systems are used in order to study the living cells through the images obtained from life cell imaging instruments.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1081

Competitive Analysis

The major players operating global life cell imaging market includes Leica Microsystems, Carl Zeiss Meditec AG, Nikon Instruments, Inc., Thermofisher Scientific, Inc., Olympus Corporation, GE Healthcare, Sigma-Aldrich Corporation, Molecular Devices LLC, PerkinElmer, Inc. and Becton-Dickinson and Company.

Rise in development of cancer drugs is a crucial factor to propel the market growth

Accelerating drug development has become a crucial factor so as to come up with new and advanced drugs that has potential to treat cancer. Understanding the cellular functionality of these oncogenic substances and tumor cells is thus a very important step in the drug development and requires high-powered microscopes to understand the dynamic structures so as to develop a drug against the cancer causing agents. The government as well as various federal agencies play important roles funding imaging systems to support and clinical care and research. For instance, the National Science and Technology Council, which is an Interagency Working Group on Medical Imaging (IWGMI) established in 2015 develops a roadmap for medical-imaging research and development in the U.S. that helps in generating better outcome of healthcare and optimize the costs.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Adult Vaccines Market Is Forecasted To Witness A Thriving Growth By 2026 Fri, 19 Apr 2019 13:11:14 +0200 http://comunicati.net/comunicati/aziende/varie/543708.html http://comunicati.net/comunicati/aziende/varie/543708.html Coherent Market Insights Coherent Market Insights The Global Adult Vaccines Market was valued at US$ 12,806.49 million in 2017 and is expected to witness a robust CAGR of 7.1% over the forecast period (2017 - 2025).

Vaccination and immunization is aids in prevention of diseases among adults and children. Vaccines are biological suspensions that contain an agent that resembles the disease causing microorganisms and are often made from inactivated microbes, toxins or surface proteins. The active agents present in the vaccine stimulates body’s immune system to recognize the disease causing agent as 'foreign substance' and develop antibodies against it. Vaccines are a preferable and highly recommended preventive measure against certain severe diseases, however, have mild side effects.

Market Dynamics

Development of vaccines for various new diseases and rising awareness regarding advantages of preventive medication are the two prominent factors supporting growth of the market. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden.

Among the middle-income and emerging economies, relevant Indian government funding agencies such as Department of Biotechnology (DBT) and The Indian Council of Medical Research (ICMR) are scaling up their investments in research and development associated to vaccine development. For instance, in 2015, the Department of Biotechnology projected a funding of US$ 2.95 million for Malaria Vaccine Initiative, to develop vaccine against Plasmodium falciparum and P. vivax.

On the other hand, growing awareness among the populace regarding prevention of diseases facilitated by vaccines is expected to augment the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden. Moreover, according to a study from the Society for Risk Analysis, 2016, GDP loss of a pandemic outbreak in the U.S. was recorded between US$ 34.4 billion and US$ 45.3 billion. However, a large population not being vaccinated poses as a restraint for growth of the market.

Among region, the market in North America held a dominant position in the global adult vaccines market in 2016. This is attributed to increasing investments facilitated by government as well as the manufacturers consistently focusing on promoting immunization in the U.S. For instance, in 2015, The Centers for Medicare & Medicaid Services (CMS), in alignment with the Centers for Disease Control and Prevention (CDC) introduced a five-year initiative named Healthy People 2020, to improve adult immunization as well as reduce the disparity rates caused majorly due to pneumonia, shingles, and influenza by working directly with physicians and provider offices, as well as with home health agencies, hospitals, beneficiaries and others under the guidance of Health Service Advisory Group (HSAG). Moreover, favorable Medicare coverage for adult vaccination in the U.S. also poses as a key factor favoring growth of the adult vaccines market.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1091

Key players operating in the global adult vaccines market include GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer, Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc.

Market players are engaged in development vaccines to cater to diseases with high epidemic

Market players are increasingly focusing on developing vaccines that caters to diseases with highest probability of causing an epidemic. For instance, in February 2017, an India-based drug firm, Cipla, in collaboration with Serum Institute of India, introduced Hepatitis B vaccine for adults in the country. The disease affects chronically over 40 million people in the country, as per India’s Universal Immunization Programme. Moreover, Dynavax Technologies Corporation received FDA approval in 2018, for its two-dosed Hepatitis-B vaccine indicated for adults aged 18 years and older.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Generic Drugs Market To Witness Widespread Expansion During 2026 Fri, 19 Apr 2019 09:31:58 +0200 http://comunicati.net/comunicati/aziende/varie/543543.html http://comunicati.net/comunicati/aziende/varie/543543.html Coherent Market Insights Coherent Market Insights Generic drugs refers to medication that have the same active ingredient as that of a branded drugs. These drugs also yield the same therapeutic effect and are prescribed in the same dosing, with the same quality, and same the way of consumption and usage. However, the inactive ingredients of generic drugs can differ as compared to their branded counter parts. These drugs are mainly marketed after a patent expiry of a branded drug and are significantly lower in costs as compared to the patented branded drugs. Generic drugs are of equivalent quality as compared to the branded drugs and are manufactured under the same safety and manufacturing procedures. Various manufacturers submit an abbreviated new drug application (ANDA) to the FDA after the completion of period of patent exclusivity. Click To Read More On Generic Drugs Market.

Patent expiry of branded drugs is a factor expected to boost growth of the global generic drugs market

Manufacturers of generic drugs are focusing on development and introduction of various innovative medication and formulation such as biosimilars. According to IMS Health data, generic drugs accounted for over 80% of the prescriptions dispensed in the U.S. in 2013. The number of patents expiring in the near future serves to be a major driver for growth of generic drugs market. For instance, Cetuximab (Erbitux) is an epidermal growth factor receptor inhibitor that is indicated in the treatment of metastatic colorectal cancer and head and neck cancer. It is manufactured under the patent by Bristol-Myers Squibb and Eli Lily Company in Europe. The drug’s patent expires in 2018 and thus, is expected to provide opportunity for a large number of market players to manufacture its generic version.

Furthermore, supportive initiative by FDA to promote development of biosimilars is encouraging manufacturers to focus towards its development. For instance, the Biologics Price Competition and Innovation Act in the U.S. gr ants 12 months patent exclusivity with higher profit margins to the first manufacturer than the conventional generic manufacturers bringing the drugs in market later. Various other factors contributing to growth of generic drugs market include rampant growth in incidence of chronic diseases.

New drug launches and market approvals from the U.S. FDA to generic manufacturers are bolstering growth of the generic drugs market. For instance, in December 2017, Zydus Phamaceuticals — a subsidiary of Cadila Healthcare — received U.S. FDA approval to market Pramipexole Dihydrochloride extended-release tablets for the treatment of Parkinson ’s disease in the U.S. market. Key players operating in the global generic drugs market are Teva Pharmaceutical Industries, Mylan N.V., Novartis International AG, Pfizer, Inc., Allergan Plc, Sun Pharmaceuticals, Fresenius Kabi, Sanofi, Endo International, Lupin Ltd., Abbott Healthcare, AstraZeneca Plc, and Novo Nordisk.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1132

Asia Pacific to gain significant traction in the global generic drugs market owing to increasing number of local players

On the basis of region, the global generic drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America held a dominant position in the global generic drugs market in 2016. This is attributed to favorable regulatory policies that are revised and amended to encourage generic drugs business in the region. For instance, Generic Drug User Fee Amendment (GDFUA) was reauthorized in 2017 after its initiation in 2012 by FDA for increasing consumer access to high quality, safe, and affordable drugs.

On the other hand, Asia Pacific is expected to show a significant traction in the market over the forecast period. This is attributed to lower manufacturing costs and high skilled workforce in the Asian countries. According to India Brand Equity Foundation, India has the second largest number of U.S. FDA manufacturing plants outside the U.S. that are involved in generic drugs manufacturing. Additionally, the cost of manufacturing is 33% lower in India than that in the U.S., increasing accessibility to generics in these countries.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Antibiotic Bone Cement and Casting Materials Market at a Rapid Pace Until 2026 Thu, 18 Apr 2019 16:25:09 +0200 http://comunicati.net/comunicati/aziende/varie/543414.html http://comunicati.net/comunicati/aziende/varie/543414.html Coherent Market Insights Coherent Market Insights Bone cement is a material used for the fixation of joint implants to the bone. Chemical bone cement is Plexiglas, which is a polymer-based material comprising poly-methyl-methacrylate (PMMA) or co-polymers. Infection during orthopedic surgery is a major concern, which makes the use of antibiotic bone cements essential. Casting materials are used for supporting broken or injured bone. These materials act as a supportive wrap or bandage around the broken bone. Casting materials are available in various shapes and sizes, however, the most common type of casting material used in antibiotic bone cement are plasters and fiberglass. Increasing incidents of falls, road-accidents, and sports injuries is expected to foster growth of Antibiotic Bone Cement and Casting Materials Market.

Increasing incidence of fatal falls is expected to boost growth of the bone cement and casting materials market over the forecast period

According to World Health Organization (WHO) 2017, falls are the second leading cause of accidental or unintentional injury deaths, worldwide. Each year an estimated 646,000 individuals die from falls, globally of which over 80% are in low and middle-income countries. Adults older than 65 years of age, are reported to be highest in number in terms of fatal falls and chances of hip fracture, knee factures are very high in this age group. Factures in knee and hip are caused by trauma, fall from height, or vehicle collision.

According to World Health Organization (WHO) 2017, yearly around 1.25 million people die and 20–50 million people experience severe injury and fractures due to road accidents. Rising number of road accidents is thus expected to boost growth of the antibiotic bone cement and casting materials market over the forecast. Sports injuries are also one of the major causes of fractures. Increasing sports and outdoor activity trend and low use of protective equipment during sports, leads to severe sports injuries in joints and this is expected to fuel the antibiotic bone cement and casting material market growth in the near future.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1195

Development of new materials is expected to aid in growth of the market

A team from the University of Limerick in 2017 developed a new type of cement, which reduces the time needed for orthopedic operations and helps broken bones to heal and conjoin more quickly. The cement mixes together with a mineral called hydroxyapatite, which is found naturally in bones and teeth. The recently approved bone cement has been used successfully in 4,000 operations and thus holds a strong competition for market players.

Key players in bone cement and casting materials market are Smith & Nephew plc, Zimmer Biomet Holdings, Exactech, BSN medical GmbH, 3M Health Care Ltd, Stryker Corporation, Orthofix International, and DePuy Orthopaedics.

Increasing number of fractures in Western Pacific and South East Asia is expected to aid in growth of the bone cement and casting materials market in Asia Pacific in the near future

On the basis of region, antibiotic bone cement and casting materials market by Coherent Market Insights is segmented in to North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Western Pacific and South East Asia are expected to be lucrative markets owing to rising prevalence of fatal falls and factures. According to WHO 2017, Western Pacific and south East Asia accounted for 60% of deaths and injuries due to fatal falls. Africa market is also expected to witness a robust growth owing to increasing incidents of accidents. According to WHO Global Status Report on Road Safety 2015, the incidents of accidents in low- and middle-income countries are more, and the accident rate in Africa is highest among all the other regions.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Companion Animal Drugs Market Trends Estimates High Demand by 2026 Thu, 18 Apr 2019 12:06:01 +0200 http://comunicati.net/comunicati/aziende/varie/543158.html http://comunicati.net/comunicati/aziende/varie/543158.html Coherent Market Insights Coherent Market Insights Companion animals are domesticated animals which are kept primarily for person’s companionship and enjoyment rather than as a livestock, working animal or laboratory animal. Companion animal include dog, cat, fish, bird, horse, rabbit, hamster, guinea pig, and ferret. According to the National Pet Owners Survey in 2017, conducted by American Pet Products Association (APPA), around 68% of the household owns a companion animal or pet in U.S. Companion animal drug include veterinary and over-the-counter drugs, supplements, nutraceuticals, vaccines, antibiotics and parasiticides, which are used in the treatment of disease associated with digestive system, immunological system, reproductive system, respiratory, and urinary system. Click To Read More On Companion Animal Drugs Market.

According to the report published by Federal Trade Commission (FTC), in 2015, U.S. spent around US$ 58 billion in 2014 on their companion animals, which include food, veterinary care, prescription, and OTC medications, and other pet services and products. Moreover, U.S. companion animal drugs market is significantly growing in both prescription and non-prescription based medications. Growing rate of companion animal ownership, progressive rate in pet health insurance, and longer life expectancy of companion animals due to the advances in animal health medication, expected to drive the growth of companion animal drugs market in the near future. According to the North American Pet Health Insurance Association (NAPHIA), in 2015, there is an increase of US$ 774 million in overall gross written premium (GWP), accounting to 17.2 percent growth in GWP. In 2015, around 1.6 million pets got secured with health insurance, increasing to 12% from 2014 to 2015.

Growing obesity in pets fuels the growth of the companion animal drugs market

According to the report by Association for Pet Obesity Prevention (APOP), in 2016, there is a continuous increase in pet obesity, affecting around 54% of dogs and 59% of cats in U.S. Pet obesity is a major problem in U.S., which increases the pain and suffering and also affects the life expectancy of companion animal or pet. According to APOP, factors causing pet obesity include negligence of pet owners and veterinary professionals in providing nutritional diet such as corn, grains, and raw and organic diet. In 2016, According to the stats by American Pet Products Association (APPA), around 41.9 million dogs and 50.5 million cats were classified into overweight or obese category by veterinary healthcare professionals.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1203

According to the Mississippi State University, College of Veterinary Medicine, consumption of high calorific diet, genetic and age factors, are some of the factors accounted for obesity in the companion animal, which further lead to osteoarthritis, diabetes mellitus, hepatic lipidosis, cardiovascular disease, and early mortality. This is expected to augment the growth of companion animal drugs market in the near future.

Key Players in the Global Companion Animal Drug Market

Some of the major players operating in the companion animal drugs market include Merck Animal Health, Elanco, Zoetis, Boehringer Ingelheim GmbH, Virbac, Ceva Sante Animale, Bayer AG, Dechra Pharmaceuticals PLC, and Vetoquinol SA.

Veterinary hospital/clinics segment are expected to become the more trusted distribution channel

According to the report by Federal Trade Commission (FTC) staff, in 2015, veterinarians and veterinary clinic or hospitals were accounted as the major distribution channel for pet medications. Nearly all major manufactures of pet medications distribute their medications through licensed veterinaries or through authorized veterinary distributors. Moreover, consumers purchase pet medications from veterinarians at the time of examination and diagnosis of their pet.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Spinal Fusion Devices Market Size & Share to See Modest Growth Through 2026 Thu, 18 Apr 2019 08:59:47 +0200 http://comunicati.net/comunicati/aziende/varie/542983.html http://comunicati.net/comunicati/aziende/varie/542983.html Coherent Market Insights Coherent Market Insights Spinal fusion devices are used in spinal surgeries for patients suffering from various spinal diseases such as degenerative disc disease (DDD) and herniated disc. Spinal fusion devices are implanted into the spinal cord of the patient. The U.S. Food & Drug Administration (FDA) has placed spinal fusion devices under Class II of medical devices category. Moderate to severe spine problems need to be treated with surgical approach such as spinal fusion wherein the spinal vertebrae are either removed and fixated with implants or fused with the help of various fusion methods. Quality of life can be improved by spinal fusion surgeries. Rising prevalence of spinal cord diseases is expected to increase adoption of these surgeries. Click To Read More On Spinal Fusion Devices Market.

Market Dynamics

Frequent approval from regulatory bodies to latest spinal fusion devices is expected to be the major driver for growth of global spinal fusion devices market over the forecast period. In 2016, Spineart Geneva SA received US Food and Drug Administration (FDA) clearance for its first range of titanium interbody, named - JULIET Ti PO, OL and TL interbody systems. The JULIETTi PO, OL and TL interbody systems are the range of titanium interbody implants. It include a full range of sizes to for diverse anatomies. The smooth bullet-shaped nose, lateral sides and chamfers of the implant are polished to preserve endplates, nerve roots, and soft tissues during insertion. The Ti-LIFE Technology micro-porous scaffold mimics the bone trabecular structure, which enables cell colonization and promotes bone ingrowth. In 2016, Centinel Spine, Inc. received U.S. FDA approval for STALIF L Minimally-Invasive Lateral Integrated Interbody System. It has advantages in minimally-invasive spinal fusion surgery. Furthermore, increasing prevalence of spinal disorder is also expected to increase demand for spinal fusions devices and hence is expected to drive spinal fusion devices market growth in near future.

Rapid product launch and frequent approval of novel spinal fusion devices are expected to drive growth of the global spinal fusion market

In 2015, Aesculap Implant Systems, a division of B. BRAUN MELSUNGEN AG, launched Modulift Vertebral Body Replacement System (VBR). It is the latest generation of expandable cage technology. In 2017, Stryker’s Spine division launched Serrato pedicle screw, a unique dual-lead screw intended for use in the non-cervical spine. In 2016, Stryker launched Aero-C Cervical Stability System at the meeting of the American Academy of Orthopedic Surgeons in Orlando. Entry of these novel products in market is expected to support the growth of global spinal fusion devices market in near future. Furthermore, frequent approvals of innovative products is also expected to drive market growth.

Competitive Landscape

Key players operating in global spinal fusion devices market include Zimmer Biomet Holdings, Inc., Inc., Stryker Corporation, Inc., Exactech, Inc., Orthofix International N.V., Globus Medical, Inc., NuVasive, Inc., Medtronic Plc., Depuy Synthes, B. Braun Melsungen AG, Wenzel Spine, Inc., K2M Group Holdings, Inc., Centinel Spine, Inc., and Spineart Geneva SA.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1211

Increasing prevalence of spinal deformities is expected to drive growth of the global spinal fusion device market

Factors responsible for spinal deformities include weight, diet, smoking, and other lifestyle factors. Early onset of degenerative spinal changes is attributed to the toxins in cigarette smoke damaging the cartilage of spine. According to World Health Organization (WHO), more than 1.1 billion people smoked tobacco in 2015 worldwide. According to a study published in SpineUniverse in 2017, disc herniation is the most common indication for spinal surgery, and around 75% of all spinal surgeries were performed for herniated disc. Increasing prevalence of spinal deformities due to unhealthy lifestyle and high chances of disc herniation are expected to drive growth of the spinal fusion devices market in near future.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Liquid Biopsy Market To Be At Forefront By 2026 Wed, 17 Apr 2019 15:08:01 +0200 http://comunicati.net/comunicati/aziende/varie/542816.html http://comunicati.net/comunicati/aziende/varie/542816.html Coherent Market Insights Coherent Market Insights Liquid biopsy gained popularity among physicians owing to increasing importance of precision medicine and advantages offered by the liquid biopsy over conventional biopsy techniques. Clinical diagnosis of tumors is done by pathological testing and medical imaging in which pathological testing involves tissue biopsies, molecular pathology tests, and serological indicators tests. Among these techniques tissue biopsy is considered as a gold standard for diagnosis. However, it has certain disadvantages such as difficulty in obtaining tissues from terminal cancer patients, complications due to sampling, and result difference due to tumor heterogeneity. Liquid biopsy provides more accurate results and offers more advantages over conventional techniques. It uses circulating tumor cell detection and cell free DNA etc. techniques for early detection of the cancer. Click To Read More On Liquid Biopsy Market.

Market Dynamics

Factors such as rising prevalence of various cancers, rising demand for minimally invasive procedures, and advantages offered by liquid biopsy over conventional tissue biopsy are supporting growth of the liquid biopsy market. Liquid biopsy offers advantages over conventional tissue biopsy such as early disease detection, real-time monitoring of the metastasis and actual treatment response, detection of primary tumors and metastasis through simple and non-invasive tests, and may be cheaper than conventional biopsy. Furthermore, prevalence of various cancers is increasing and according to National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer are diagnosed in the U.S., with an around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024, indicating need for early disease diagnosis and treatment. Demand for minimally invasive treatments is also increasing as tissue biopsy is an invasive approach for cancer diagnosis, wherein, liquid biopsy is more convenient, which is expected to boost growth of the liquid biopsy market.

A liquid biopsy is a simple and non-invasive technique that enables to discover a range of information about a tumor through a simple blood sample. Some of the commercially available liquid biopsy tests for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and Target Selector liquid biopsy assays. A liquid biopsy test can detect epidermal growth factor receptor (EGFR) gene mutations, evident in non-small cell lung cancer (NSCLC). The process requires only 5 milliliters of blood and is quicker than a surgical biopsy. The blood sample is processed to get 2 milliliters of plasma that is analyzed for tumor DNA. Potential of liquid biopsies to detect disease progression or treatment resistance long before it would trigger clinical symptoms or appear on imaging scans is major factor driving growth of liquid biopsy market.

Tissue samples removed for biopsy many not show all mutations as cancer has multiple genetic mutations, whereas liquid biopsies offer an improved chance of detecting these genetic changes. Moreover, the efficiency of liquid biopsy to improve progression and survival rates in cancer is major factor driving growth of the market.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1223

Manufacturers are focusing on development of new tests in the liquid biopsy market and this is expected to bolster growth of the liquid biopsy market over the forecast period

Established as well as small players in the liquid biopsy market are actively focusing on research and development of methods in liquid biopsy through collaborations. For instance, Biodesix—a U.S.-based company—developed a novel way of extract circulating RNA from plasma in November 2017, in collaboration with Norgen Biotek. Moreover, Precipio—a U.S.-based organization, entered into merger agreement with Transgenomic, in 2017, for commercializing ICE COLD PCR (ICP) for liquid biopsies, which preferentially enriches mutant DNA sequences over wild-type DNA through selective amplification. HaploX Biotechnology—a China-based company—raised US$ 32 Mn in financing, in January 2018, in order to integrate liquid biopsy technology, artificial intelligence, and gene sequencing.

Competitive Landscape

Some major players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Hematopoietic Stem Cell Transplantation (HSCT) Market Upcoming Trends, Demand and Analysis Till 2026 Wed, 17 Apr 2019 11:19:29 +0200 http://comunicati.net/comunicati/aziende/varie/542639.html http://comunicati.net/comunicati/aziende/varie/542639.html Coherent Market Insights Coherent Market Insights Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources namely, autologous that uses stem cells from the patient’s own body and allogeneic that sources stem cells from a donor’s body. Click To Read More on Hematopoietic Stem Cell Transplantation (HSCT) Market.

Rising incidence of leukemia and lymphoma and continuous research on hematopoietic stem cells are expected to drive market growth

As per 2017 report by Leukemia and Lymphoma Society, the U.S. alone is expected to account for a prevalence of 8,16,834 and incidence of 80,500 for lymphoma. Increasing rate of incidence is in turn, expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market. Increasing awareness about stem cell therapies among the population is also expected to propel growth of the hematopoietic stem cell transplantation market. As per survey by World Network for Blood and Marrow Transplantation (WBMN), around one million hematopoietic stem cell transplantation procedures were performed during 2006 to 2014, which indicates potential opportunities for market players.

However, high costs associated with hematopoietic stem cell transplantation procedures are expected to hinder growth of the market. Other factors such as difficulty in finding a donor for allogeneic transplantation, technological barriers (currently used culture technologies, point of care delivery, and lack of analytical assay), and side effects such as graft vs. host disease, are also expected to slow down growth of the hematopoietic stem cell transplantation market.

Important players present in the hematopoietic stem cell transplantation market

Major players operating in the hematopoietic stem cell transplantation market include Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc, TiGenix N.V., Escape Therapeutics Inc., Bluebird Bio, and Cellular Dynamics International.

Increasing adoption of the growing trend of personalized medicine is expected to drive growth of the hematopoietic stem cells transplantation market. A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1250

In March 2017, Gilead Sciences announced the acquisition of Kite Pharma, which produces products such as Axi-cel to treat non-Hodgkin lymphoma. Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017.

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Genome Engineering Market Progresses for Huge Profits by 2026 Wed, 17 Apr 2019 08:38:13 +0200 http://comunicati.net/comunicati/aziende/varie/542543.html http://comunicati.net/comunicati/aziende/varie/542543.html Coherent Market Insights Coherent Market Insights The Global Genome Engineering Market was valued at US$ 2,582.7 Mn in 2016 and is expected to witness a CAGR of 14.3% over the forecast period (2017–2025).

Genome engineering is a technique in which a DNA is inserted, deleted, modified or replaced in the genome of a living organism. Research and development activities are conducted in genome engineering for the development of novel technologies. For instance, in 2017, Synthego Corporation launched a CRISPR Pioneers Program to expand genome engineering research. Researchers are majorly focusing on developing treatments for cancer and rare diseases with the help of genome engineering tools such as CRISPER. Many genome technologies are under trial for treatment of such diseases, and are expected to receive approvals in the near future.

Market Dynamics

Development of novel technologies in genome engineering field is expected to significantly drive growth of the global genome engineering market in the near future. For instance, in 2017, Merck KGaA— Germany-based company—developed a new genome editing tool dubbed 'proxy-CRISPR', providing access to previously inaccessible microenvironments of the genome by modification of chromatin modifications. In 2017, Benson Hill Biosystems, Inc.—an agricultural technology company—launched its latest CRISPR 3.0, to increase innovators’ access to gene editing. CRISPR 3.0 is a latest innovative genomics tool, which is expected to improve crop performance. Development of such novel technologies by major key players is expected to create a conducive environment for growth of market.

Furthermore, increasing strategic collaborations by major key players for genome engineering technologies is also expected to drive market growth. For instance in 2015, ToolGen, Inc.—a South Korea-based company—collaborated with Thermo Fisher Scientific and licensed its CRISPR/Cas9 intellectual property portfolio to Thermo Fisher Scientific. This license agreement has strengthened the relationship between ToolGen and Thermo Fisher in the area of genome editing. In 2014, Cellectis Bioresearch and Thermo Fisher Scientific entered into a strategic collaboration agreement covering the uses of TAL nucleases under the brand name TALEN. As per the agreement, Thermo Fisher Scientific is granted a worldwide license under Cellectis’ rights to the TAL nucleases outside the therapeutic field. Thermo Fisher will market TALEN for these applications under its Life Technologies brand. In 2014, Bluebird Bio, Inc. acquired Precision Genome Engineering (Pregenen) at US$ 139.9 Mn. This acquisition has helped the company to use Pregenen’s MegaTALs, originally developed by Precision Genome Engineering. In 2014, Biogen Idec and Sangamo BioSciences, Inc. entered into a collaboration agreement for the development of treatment of Hemoglobinopathies. According to the collaboration, Biogen Idec will use Sangamo's proprietary zinc finger nuclease (ZFN) genome-editing technology.

High cost of genome engineering technologies is expected to be the major factor, restraining growth of the genome engineering market over the forecast period. For instance, according to the fees chart provided by Yale Genome Editing Center, in 2018, it charges between US$ 8,000 and US$ 15,000 for gene editing facilities. The high cost associated with genome engineering facilities is expected to hamper the market growth, especially in emerging economies such as India, Brazil, and South Africa. Moreover, genome engineering is a very complex technology and needs high skilled researchers, which limits its adoption rate.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1262

Key players operating in the genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.

Moreover, increasing funding and investments for the development and research of new genetic engineering technologies is also expected to drive market growth. For instance, in January 2018, the U.S. National Institutes of Health (NIH) announced to grant US$ 190 million for genome editing research. This new program, Somatic Cell Genome Editing, will award funds to biomedical researchers over the following six years. The support from major research organizations such as NIH is expected to attract more researchers in this field, which may lead to advancements in technology and also aid in growth of the market.

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Blood Clotting Factors Market Predicted to Grow at a Moderate Pace Through 2026 Tue, 16 Apr 2019 15:15:18 +0200 http://comunicati.net/comunicati/aziende/varie/542403.html http://comunicati.net/comunicati/aziende/varie/542403.html Coherent Market Insights Coherent Market Insights Blood clotting factors are proteins or enzymes that control bleeding. Blood clotting or blood coagulation is a process in which blood gets converted into solid clots at time of any wound or break down of blood vessels. Clotting can prevent death from bleeding and also restrict the entry of bacteria and viruses into the body. Haemostasis is the mechanism for blood clotting, which in controlled by a number of factors called blood clotting factors. Deficiency of these factors can cause blood clotting diseases such as haemophilia and von willebrand disease (VWD). According to Centre for disease control and prevention (CDC), 2017, around 20,000 males were suffering from Haemophilia in the U.S. Click To Read More On Blood Clotting Factors Market.

Approval of novel drugs in key markets such as North America and Europe is expected to boost the growth in blood clotting factors market

In November 2017, the U.S. FDA approved Hemlibra (Emicizumab-kxwh) developed by Roche AG, for the treatment of Haemophilia A patient with inhibitors. This was the first approval by FDA in about 20 years to treat people with hemophilia A with inhibitors. Moreover, FDA approved Shire Plc’s Adynovate for treatment of hemophilia A patients. The drug has also been approved for use in surgical setting for both category of patients, adult and pediatric. In January 2018, the drug (Adynovate) was granted marketing authorization in European Union (EU). In EU, the drug got approval for adults and adolescents suffering from Hemophilia A. These approvals will provide the alternate option for patients suffering from hemophilia. Introduction of these drugs in market is expected to propel growth of the blood clotting factors market over the forecast period.

Low adherence to treatment among patients with Hemophilia has hindered the growth in this market. According to The National Haemophilia Foundation, about 75% of people suffering from hemophilia either don’t receive or don’t have access to complete treatment.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1301

Key players operating in Blood clotting factors market include Shire Plc, Baxter International Inc., Grifols International SA, Roche AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Biogen Idec, and Kedrion S.P.A.

North America is expected to hold a dominant position in blood clotting factors market, owing to increased awareness about the disease and availability of wide range of treatment options

Haemophilia is a rare disorder affecting very small fraction of population across the globe. Pharmaceutical companies invest less amount on development of such drugs due to low return on investment. However, FDA has recognized this fact and has formulated favorable policy to motivate companies to invest in this area. Orphan Drug Act that applies to company operating in this area provides three special incentives i.e. 7 years exclusivity period, tax credit and waiver of prescription drug user fees. Due to such policy, the company has invested in rare disease research which has led to development of products such as Hemlibra (Emicizumab-kxwh), Adynovate and Others. Furthermore, increasing awareness regarding rare disease in developed economies such as U.S. and Canada has resulted in high number of patients receiving treatment. Owing to above mentioned factors, North America has dominated the market and it is also expected to retain position over the forecast period. Asia Pacific is expected to witness robust growth in the market due to improved ratio of patients suffering from disease and patients receiving treatment. Availability of generic products, at much lower price compared to branded product, in the market is expected to fuel growth of the market in Asia Pacific.

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Fetal and Neonatal Care Equipment Market Demands and Growth Prediction 2018 to 2026 Tue, 16 Apr 2019 13:18:48 +0200 http://comunicati.net/comunicati/aziende/varie/542261.html http://comunicati.net/comunicati/aziende/varie/542261.html Coherent Market Insights Coherent Market Insights The Global Fetal and Neonatal Care Equipment Market is estimated to be valued at US$ 7,279.5 million in 2017 and is expected to witness a CAGR of 7.4% over the forecast period (2017 – 2025).

Fetal monitoring is required to constantly monitor health of the unborn baby and ensure a safe birth. Equipment, which helps to assist in diagnosis, monitoring or treatment of newborn babies are neonatal care equipment. Healthcare professionals perform fetal monitoring during pregnancy and labor, as that process is crucial for keeping the mother and the child safe and healthy. Growth in fetal and neonatal care equipment market is attributed to increasing rate of birth and preterm births.

Market Dynamics

Fetal and neonatal care is critical during and after pregnancy, as the fetus and neonates are prone to infections and diseases, owing to low immunity. Therefore, regular diagnosis and monitoring is essential. In emerging economies such as those in Africa, increasing number of at-home births results in high mortality rate. According to NCBI data, 2015, Zambia is one of the sub-Saharan African countries with a high maternal mortality ratio (MMR), and the demographic and health survey (DHS) showed that the country’s MMR is 591 maternal deaths per 100,000 live births. Fetal and neonatal care equipment manufacturers are focusing on offering high-end, home-based infant care and neonatal solutions and this is expected to be one of the major factors driving growth of the market. For instance, in February, 2017, Masimo received CE marking for Eve — a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97 Pulse CO-Oximeter. Eve is integrated with Masimo SET Measure-through Motion and Low Perfusion pulse oximetry with a pre-ductal to post-ductal synchronization algorithm designed to reduce calculation errors and in turn saving newborn lives.

Key players operating in the global fetal and neonatal care equipment market include Koninklijke Philips N.V., General Electric Company, Medtronic plc, Dragerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., FUJIFILM SonoSite, Inc., Masimo, Natus Medical Incorporated, Atom Medical Corporation, and CooperSurgical Inc.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1319

Increasing government initiatives for fetal and neonatal care is expected for growth of the market

Various government and non-government organizations are actively taking initiatives to provide better maternal and fetal care. Moreover, rise in number of problems during pregnancy due to high-blood pressure, diabetes, preterm labor affects the fetus. So, fetal and neonatal care devices are routinely used by gynecologist and obstetrics to examine fetal or babies’ health during labor and delivery. According to National Institute of Health, Newborn screening programs across the U.S., screen four million infants each year. This public health program detects treatable disorders in newborns, allowing treatment to begin, often before symptoms or permanent problems.

North America is expected to account for highest market share in the global fetal and neonatal care equipment market, owing to the presence of a better reimbursement structure, development of well-equipped neonatal intensive care unit by hospitals. The Newborn Intensive Care Unit (NICU) at Brigham and Women’s Hospital (BWH) is a 60-bed Level III newborn intensive care unit that provides complex multidisciplinary care to more than 3,000 babies each year. Moreover, Asia Pacific is expected to witness high growth in the global fetal and neonatal care equipment market. This is owing to increasing incidences of premature births, high birth rates in countries such as India and China, and increasing healthcare awareness are the factors boosting growth of the market in this region.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Empty Capsules Market Provides An In-Depth Insight Of Sales And Trends Forecast To 2026 Mon, 15 Apr 2019 16:56:47 +0200 http://comunicati.net/comunicati/aziende/varie/541777.html http://comunicati.net/comunicati/aziende/varie/541777.html Coherent Market Insights Coherent Market Insights The Global Empty Capsules Market was valued at US$ 1.55 billion in 2016 and is expected to witness a robust CAGR of 7.7% over the forecast period (2017–2025).

Shell component and composition are important factors while manufacturing empty capsules. Gelatin or a non-gelatin polymeric material such as hypromellose, water, starch, and plasticizer is used in manufacturing hard or soft gelatin capsule shells. Different coatings can be used on shells in order to achieve the desired therapeutic action once the capsule is administered to the patient. For instance, enteric coated capsules are designed to release the drug in the intestine. Moreover, sustained release capsules are designed to release the drug ingredients slowly over a longer duration of time. Capsules can also be manufactured to achieve local effect, while bypassing the first pass metabolism such as rectal capsule, which are inserted into the rectal cavity. However, requirement of a capsule filling machine is important as filling each capsule by hand is time consuming.

Market Dynamics

Manufacturers can mix active pharmaceutical ingredients according to their need and can prepare a dosage form according to the requirement with the help of empty capsules. Capsules offer an easy way to administer drugs as these are easy to disintegrate, easy to swallow, and have faster dissolution times than other oral solid dosage forms. Advancement in technology such as sustained release dosage and extended release dosage in capsules, to achieve the required effects is expected to be factor for growth of the market. Advantages offered by capsules over tablets such as improved palatability and freedom to administer solid as well as semisolid drugs is driving growth of the empty capsules market. Furthermore, patients with kidney or liver problems can take the supplements through vegetarian capsules with no side effects as excretion of additional protein (present in gelatin capsules) from the body is difficult. These factors are expected to impact the empty capsules market over the forecast period.

Advantages offered by capsules over conventional solid dosage forms is expected to drive growth of the empty capsules market

Capsules offer various advantages over other solid dosage forms such as tablets. One of the important advantage is that capsules can deliver solid as well as non-aqueous liquids and semisolid doses. Most of the active pharmaceutical ingredients such as vitamins, herbs, drug substances are not palatable. Capsules can play an important role in masking the taste of the drugs. Children find it hard to swallow liquid dosage forms of vitamin supplements such as castor oil and other fish oils, and can be effectively administered with capsules. Herbal products such as Cheyenne pepper are spicy (hot) and are hard to swallow, which can be effectively administered through gelatin capsules. Empty capsules are available in a variety of sizes, which can aid in dose calibration and customization according to individual needs. Active pharmaceutical ingredients, which cannot be compressed easily into tablets, can be administered using empty capsules.

Competitive Landscape

Some players operating in the global empty capsules market are ACG Associated Capsules Pvt. Ltd., Capsugel, Inc., CapsCanada Corporation, Medicaps Ltd., Qualicaps, Inc., JC Biological Technology Co., Patheon, Inc., Roxlor LLC, and Sunil Healthcare Ltd.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1328

Introduction of different types of materials for capsule manufacturing is supporting growth of the empty capsules market

Gelatin has widely been used material for empty capsules and is obtained from natural sources such as bovine gelatin and porcine gelatin. Two types of capsules can be manufactured using gelatin such as hard gelatin capsules and soft gelatin capsules. However, these capsules have limitations owing to the nature of gelatin as certain compounds cannot be mixed with gelatin such as highly water soluble compounds. Introduction of other compatible materials has widened the scope of applications for these products. For instance, introduction of non-gelatin capsules, which are synthetic (hydroxypropylmethyl cellulose) as well as vegetarian capsules has aided in growth of the market. Vegetarian capsules such as pullulan are made from tapioca plant and offers several advantage over gelatin capsules. Vegetarian capsules cause lesser allergies as compared to other forms.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Transplant Diagnostics Market Poised to Take Off by 2026 Mon, 15 Apr 2019 14:43:40 +0200 http://comunicati.net/comunicati/aziende/varie/541683.html http://comunicati.net/comunicati/aziende/varie/541683.html Coherent Market Insights Coherent Market Insights Transplant diagnostics involves assessing compatibility between organ donor and receiver so as to predict any future organ rejection episodes and have contingencies in place. Number of tests are performed such as ABO blood group compatibility, tissue typing, cross matching, panel reactive antibody test, serology screening, and testing for infectious diseases. Increased understanding of the organ rejection phenomenon has led to identification of robust biomarkers along with development of robust biomarker identification tests. The Global Transplant Diagnostics Market was valued at US$ 544.2 million in 2016 and is expected to witness a robust CAGR of 8.4% over the forecast period (2017–2025).

Technological advancements in the molecular and non-molecular assays such as PCR, and NGS has increased the data throughput. However, high cost of transplant diagnostic products, limited medical reimbursement, and low awareness about organ transplantation in emerging economies such as Middle East and Asia Pacific is expected to be a factor hindering the transplant diagnostics market growth.

Market Dynamics

Rising prevalence of chronic diseases leading to multiple organ failures; benefits offered by transplant diagnostics, which can predict organ rejection episodes and help in preparing a contingency plan; increasing government initiatives for organ donation awareness; and research and development by leading players to enhance transplant diagnostic products is expected to boost growth of the transplant diagnostics market over the forecast period. For instance, Natera, Inc. and University of California, San Francisco (UCSF), announced a research collaboration in 2016, to study DNA markers of Kidney Transplant Rejection. Furthermore, in 2016, the U.S. government announced plans to invest US$ 200 million to shorten the waiting list of organ transplant patients. These factors are expected to aid in growth of the market over the forecast period.

Advancement in technology in diagnostics is expected to drive growth of the transplant diagnostics market

Advent of new diagnostic tests have improved medical outcomes associated with organ transplants. Organ rejection rate can be minimized by matching the donor and recipient compatibility before transplantation. Conventional techniques in transplant diagnostics include analysis of human leukocyte antigen (HLA). HLA analysis is done in high-throughput laboratories with a limited staff, which is time consuming. However, presence of molecular assay technologies, such as sequencing techniques and PCR-based assays have proved to be efficient.

Genetic information can be interpreted on a large scale by using advanced next generation sequencing (NGS) technologies at an affordable price. For instance, Illumina’s MiSeq system offers high-resolution HLA typing and uses next generation sequencing technology, which can be used by any laboratory. In December 2015, Immucor and Sirona Genomics introduced MIA FORA NGS—a high-resolution HLA typing solution—that provides accurate and detailed coverage of 11 HLA genes. Furthermore, HLA analysis at the DNA level is possible due to technologies such as PCR-RFLP, PCR-SSP, PCR-SSO, PCR-SSCP, and PCR-SNP.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1335

Key Companies

Some major players operating in the transplant diagnostics market are Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., F. Hoffman-La Roche Ltd., Immucor, Inc., Becton Dickinson and Company, bioMérieux S.A., Illumina, Inc., CareDx, Inc., and GenDx.

Government initiatives to promote organ transplantation along with awareness initiatives for the same is supporting growth of the transplant diagnostics market

Increasing number of transplantation is expected to increase demand for transplant diagnostics, in order to reduce episodes of organ rejection. Various organizations such as World Health Organization (WHO) and World Health Assembly have implanted action plans such as WHA57.18 to increase awareness regarding transplantation. National Health Service (NHS) Blood & Transplant funded a living transplant initiative in 2016, which was led by the National BAME Transplant Alliance, to increase the number of living transplants from black, Asian, and minority ethnic (BAME) communities. Moreover, in 2015, the Health Resources and Services Administration in the U.S. initiated the Organ Donation and Transplantation Funding program and allocated US$ 24 million for research.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Electric Dental Handpiece Market: Effect and Growth Factors Research and Projection 2018- 2026 Mon, 15 Apr 2019 11:58:04 +0200 http://comunicati.net/comunicati/aziende/varie/541477.html http://comunicati.net/comunicati/aziende/varie/541477.html Coherent Market Insights Coherent Market Insights Electric dental handpieces are devices by dentist to perform various procedures such as cavity preparation, crown preparation, decay removal, and endodontics. Electric dental handpieces utilizes electric motor, which is attached to a shaft with gears and these gears are attached with bur (part that performs actual cutting). Whereas, air driven dental handpiece run on compressed air that rotates the turbine, which rotates the bur. These electric handpieces have several advantages over air driven dental handpieces such as consistent speed and torque. Electric dental handpieces offer speed control (RPM from 100 to 2, 00000) and higher torque (greater cutting power), and produces less noise and less vibration, hence does not produce heat in the operating area. Other advantages include greater accessibility, more precise operation, and no malfunction of turbine as compared to air driven handpiece. Click To Read More On Electric Dental Handpiece Market

High prevalence of oral diseases is expected to drive growth of the electric dental handpiece market

Rising prevalence of oral diseases is expected to propel growth of the electric dental hand piece market. According to FDI World Dental Federation’s Oral Health Atlas, 2015, oral disease affected 3.9 billion people worldwide, with untreated tooth decay that impacts approximately 44% of world’s population. According to World Health Organization’s Oral Health factsheet, 2012, globally, 60–90% of schoolchildren and around 100% adults have tooth decay, often leading to pain and discomfort. Another factor for growth of the market is increasing aging population. For instance, according to WHO (World Health Organization) Oral Healthcare factsheet, 2012, globally, around 30% of people with age 65-75 years have no natural teeth and burden is expected to increase. Need for dentist across the globe is increasing, for instance according to WHO factsheet in 2017, 93% of its member nations has less than 1 dentist per 1000 population, electric dental hand piece market would prosper in near future as it is integral part of dentistry setup .

Advancements in technology and continuous improvement in dental hand pieces is another factor further expected to drive growth of the electric dental hand piece market. For instance, in August 2017, KaVO Dental GmbH launched electromatic series, which provides constant torque, controlled speed, low noise operation, and increased versatility, which would make transition from air driven handpiece to electric driven hand piece, easy for dentists. Other factors such as increasing demand for cosmetic dentistry would further aid in growth of the electric dental handpiece market, report by The American Association of Oral and Maxillofacial Surgeons in 2016 has estimated that 69% of adults between the ages of 35 and 44 have lost at least one permanent tooth so they opts for cosmetic dentistry.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1366

North America and Europe are expected to exhibit high growth in the global electric dental hand piece market over the forecast period

Regions such as North America and Europe are expected to exhibit high growth in the global electric dental handpiece market, due to various factors such as increasing aging population, availability of high end dentistry instruments, and easy access of these devices to dentist. According to Centre for Disease Control and Prevention, 2012, 47.2% of adults over 30 years of age and older have some form of periodontal disease and 70.1% of adults aged 65 and above have periodontal disease in U.S. Europe is expected to be major market, owing to increasing expenditure of people in the region on oral health. For instance, according to report by Oral Health Platform of European Union, 2012, 27 European countries, together, accounted for US$ 97 billion expenditure, which is highest in world. North America market is in transition phase from air driven to electric driven hand pieces.

Key players in the global electric dental handpiece market are KaVo Dental GmbH, A-dec Inc., Dentsply Sirona Inc., Nakanishi Inc., Bien-Air Medical Technologies, DentalEZ Group, SciCan Ltd. Brasseler USA, W&H Group, Dentamerica Inc., Lares Research, J. Morita Corporation, and Being Foshan Medical Equipment Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Back Pain Therapy Market Value Projected to Expand by 2018-2026 Thu, 11 Apr 2019 18:49:09 +0200 http://comunicati.net/comunicati/aziende/varie/540621.html http://comunicati.net/comunicati/aziende/varie/540621.html Coherent Market Insights Coherent Market Insights Back pain is mainly caused due to muscular strains, strained ligaments, and muscular spasms in any region of the back. Chronic diseases such as herniated discs, arthritis, and osteoporosis can lead to back pain. Depending on the severity of the symptoms, back pain can be categorized- into acute and chronic back pain. Acute pain is most common type of back pain, which can be treated by medication. Click To Read More On Back Pain Therapy Market.

Increasing prevalence of back pain among geriatric population is expected to boost growth of the global back pain therapy market

According to study published by Centre for Disea0se Control and Prevention (CDC) in 2012, around 20.3% of population was suffering from lower back pain in U.S. Moreover, according to study published by American Chronic Association in 2010, around 80% of population is projected to experience back pain once in a life. Therefore, increasing prevalence of back pain is expected to propel demand for back pain treatment, which in turn is expected to drive growth of global back pain therapy market over the forecast period. Furthermore, increasing ageing population is also expected to drive growth of the market, as chances of back pain increases with the age. According to study published by National Centre for Biotechnology Information (NCBI) in 2015, around 19.6% of individuals aged between 20 to 60 years were suffering from low back pain worldwide. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) 2016, around 547 million people were above 60 years in Asia Pacific region and number is projected to reach around 1.3 billion by 2050. Increasing geriatric population in key regions such as North America, Europe, and Asia Pacific is expected to drive growth of the global back pain therapy market.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1374

Key Companies

Key players operating in back pain therapy market include Celebrex, H.J. Harkins Company, Inc., Pfizer, Inc., Cipla Ltd., Apotex Inc., Jubilant Generics Ltd, Purdue Pharma L.P., Johnson & Johnson, Lupin Ltd., and Teva Pharmaceutical Industries Ltd.

North America is expected to hold a dominant position in global back pain therapy market, owing to development of new therapies

In 2017, U.S.-based Pfizer Inc. and Eli Lilly and company received the U.S. Food and Drug Administration (FDA) fast track designation for its drug tanezumab, which is indicated for the treatment of chronic low back pain. Tanezumab is a humanized monoclonal immunoglobulin G2 (IgG2), which could be used as an alternative to opioids. The development of such novel drugs in the U.S. is expected to drive growth of the market in North America. Asia Pacific is expected to be the second largest market for global back pain therapy market due to increasing prevalence of back pain in ageing population. According to a study published by United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) in 2016, Asia Pacific region constitutes around 60% of the world’s geriatric population. According to study published by World Health Organization (WHO) in 2016, an estimated one out of six people in India are projected to suffer from arthritis once in life.

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Lipid Analysis Devices Market Expansion to be Persistent During 2026 Thu, 11 Apr 2019 17:12:06 +0200 http://comunicati.net/comunicati/aziende/varie/540614.html http://comunicati.net/comunicati/aziende/varie/540614.html Coherent Market Insights Coherent Market Insights The lipid analysis devices are used for measuring elevated plasma cholesterol or triglycerides or low level of high-density lipoprotein (HDL). The determination of blood lipid levels is important for monitoring the risk of cardiovascular disease. Lipid analysis device is used for detection of hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, hyperlipoproteinemia, and tangier disease. Lipid analysis device can be implemented at the clinics or it can be a point-of-care device. Point-of-care device has wider application as compared to clinical analyzers due to its low cost, accuracy, ease of use, and rapidity of producing results. The lipid analysis devices market is propelled by rising incidence of abnormal levels of lipids and technological advancements while factors such as high pricing of clinical based analyzers and stringent as well as time consuming regulatory policies are expected to hamper growth of Lipid Analysis Devices Market.

Lipid Analysis Devices Market Drivers

The lipid analysis test results were subjected to many drawbacks during patient handling such as inaccuracy in the results due to improper fasting and medications, human error, and various other factors, which gives false negative or false positive results. Therefore, to overcome such drawbacks, lipid analysis market demands for new technology-based devices, which will propel growth of lipid analysis devices market. According to the American Diabetes Association, heart attack or stroke affect people with diabetes more than twice as often as people without diabetes. Therefore, Polymer Technology Systems Diagnostics, in 2013, introduced CardioChek Plus analyzer at the annual American Association for Clinical Chemistry (AACC), which can be used for analyzing both lipid and glucose levels simultaneously. Furthermore, the CardioChek Plus analyzer system is Wi-Fi enabled and can transmit test results of patients to data collection applications. In 2013, Acon Laboratories, Inc., launched the Mission Cholesterol Monitoring system, which can perform 3 tests; total cholesterol (CHOL), high density lipoprotein (HDL), and triglycerides (TRIG).

Lipid Analysis Devices Market – Competitors

Polymer Technology Systems, Inc., Jant Pharmacal Corporation, Alere, F. Hoffmann-La Roche Ltd., Acon Laboratories, Inc., and Cholestech Corporation are some of the major players in the lipid analysis devices market. The strategies such as merger, acquisition or collaboration by key players will expand the lipid analysis devices market. For instance, in 2014, Polymer Technology Systems Inc. signed distributor agreement with Hanson Medical Systems, Inc. for domestic sales of products, which includes marketing, selling, and distributing of the CardioChek family of products to the customers.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1488

Lipid Analysis Devices Market – Regional Analysis

On the basis of region, the global lipid analysis devices market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Lipid analysis devices market is predominant in Europe region due to sedentary lifestyle and high fat diet, which contributes to increasing incidence of abnormal levels of lipid leading to cardiovascular disease. According to the World Health Organization (WHO), in 2008, around 133 million people suffered from bad cholesterol in 5 economies of European Union, which includes Germany, France, Italy, Spain, and UK. Moreover, Asia Pacific is expected to be the fastest growing lipid analysis devices market region due to increasing healthcare awareness and diagnostic demand.

According to the Centers for Disease Control and Prevention (CDC), in 2015, high blood cholesterol was the leading cause of death in the U.S. and people with high cholesterol had about twice the risk of heart disease, as compared to people with lower cholesterol level. Such high prevalence of high cholesterol and coronary heart disease globally is expected to propel growth of the lipid analysis device market. Furthermore, increasing awareness of lipid analysis devices especially kits among the population is expected to drive growth of the market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Fibrosarcoma Drugs Market To Be At Forefront By 2026 Wed, 10 Apr 2019 13:17:36 +0200 http://comunicati.net/comunicati/aziende/varie/540106.html http://comunicati.net/comunicati/aziende/varie/540106.html Coherent Market Insights Coherent Market Insights Fibrosarcoma is a rare type of soft tissue malignant tumour composed solely of fibre-forming connective tissue called as fibroblasts. Although, this condition can occur at any age, it is commonly diagnosed between the age of 30-60 years. Patients suffering from genetic conditions such as retinoblastoma, nevoid basal cell carcinoma syndrome are more prone to develop fibrosarcoma. However, precise cause of disease is unknown. Furthermore, individuals undergoing radiation therapy or having lymphedema or get exposed to chemicals such as thorium dioxide vinyl chloride or arsenic are more prone to fibrosarcoma. Click To Read More On Fibrosarcoma Drugs Market

This disease is symptomized by muscular pain, which increases exponentially with time. It is diagnosed by bone lesions in radiograph, followed by advanced imaging and laboratory test and confirmed by biopsy results. Treatment of the disease depends on the stage of tumour during diagnosis. Surgery and radiation therapy are the treatment used for fibrosarcoma.  Currently, limited number of treatment methods and various side effects of chemotherapy such as hair loss or low blood platelet count are propelling demand for research and development activities in fibrosarcoma treatment.

Fibrosarcoma Drugs Market Driver

Increasing research activities are expected to fuel the growth of fibrosarcoma drugs market over the forecast period. Fibrosarcoma being malignant tumor requires early removal through complete eradication of malignant cells by chemotherapy. Currently available chemotherapy includes side-effects such as acquirance of multi-drug resistance (MDR), severe side-effects and high rate of reoccurrence, which in turn demands for safer drug for chemotherapy. For instance, Loxo Oncology Inc., 2017, received US FDA approval for investigational new drug application for LOXO 195, a next-generation TRK inhibitor for treatment of patients with cancers that have acquired resistance to initial TRK therapy such as larotrectinib. Moreover, in the same year, LOXO oncology announced partnership with Bayer for the global development and commercialization of Larotrectinib and LOXO-195. The novel drug combination studies, clinical trial for targeted drug delivery and genetic profile based medication are expected to boost growth of the fibrosarcoma drugs market over the forecast period.

Increasing prevalence of fibrosarcoma is expected to augment growth of the fibrosarcoma drugs market. According to American Society of Clinical Oncology, 2017, around 3260 individuals were diagnosed by primary bone cancer in U.S. out of which 4% of adults are suffering from fibrosarcoma and prevalence of the disease is higher in men than in women. Currently, diagnosis facility lacks in early and accurate detection of fibrosarcoma. Therefore, rising awareness for disease and advancement in diagnostic as well as therapeutic procedures are expected to propel growth of the fibrosarcoma drugs market. Furthermore, companies, universities, and institutes are taking initiatives to provide inexpensive, readily available drugs with less side-effects as compared to present drugs that will help key players to strengthen product portfolio, in turn driving growth of the fibrosarcoma drug market.

Fibrosarcoma Drugs Market- Competitor

Major players operating in fibrosarcoma drugs market include Cadila Healthcare Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Baxter International Inc., Eli Lilly and Company, Pfizer limited, Johnson & Johnson., and Celon Laboratories Pvt. Ltd.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1495

Key players as well as government organization such as Nation Cancer Institute or American Society of Clinical Oncology sponsors or collaborate for the development of novel therapies and drugs. For instance, Bayer partners with loxo oncology to develop and commercialise cancer therapies. Furthermore, Bristol-Myers Squibb Company acquired IFM therapeutics, 2017, to acquire right on preclinical stimulator of interferon genes (STING) and NLRP3 agonist programs, which are focused on enhancing the innate immune response for tumour.

Fibrosarcoma Drugs Market- Regional Analysis

The global fibrosarcoma market is projected to hold dominant position in North America over the forecast period, due to increasing research activities leading to better fibrosarcoma treatment. Furthermore, well-developed healthcare infrastructure is fuelling growth of fibrosarcoma market. Asia Pacific is expected to be fastest growing market over the forecast period due to developing healthcare infrastructure and rising awareness regarding conditions of fibrosarcoma.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Point-of-Care Diagnostics Market Usage, Dosage And Side Effects Analysis 2018 to 2026 Wed, 10 Apr 2019 10:07:11 +0200 http://comunicati.net/comunicati/aziende/varie/539974.html http://comunicati.net/comunicati/aziende/varie/539974.html Coherent Market Insights Coherent Market Insights The Global Point-of-Care Diagnostics Market was valued at US$ 18,219.4 million in 2016 and is expected to witness a robust CAGR of 9.2% over the forecast period (2017 – 2025).

Cancer prevalence is increasing worldwide and often it is diagnosed in late stage, which affects the medical decision significantly. As cancer may be potentially cured if diagnosed in early stages, the importance of rapid point of care diagnostic tests is increasing in medical sector. Currently, cancer diagnosis is done by invasive techniques such as biopsy. Rapid biomarker identification tests are not present in extensive number. The U.S. Food & Drug Administration has approved breast cancer test in March 2018, offered by the company 23andMe. This cancer test is capable of diagnosing three of the 1000 mutations in the BRCA1 and BRCA2 genes associated with increased risk of breast, ovarian, and prostate cancer. Cancer point of care diagnostic/biomarker testing holds huge potential for market growth, as there is no significant competition in this sector.

Market Dynamics

Demand for point of care testing is increasing, owing to factors such as lack of access to centralized laboratories in emerging economies such as Asia Pacific, independence from centralized laboratories as the testing can be done on the spot without the need of laboratory facilities, and rapid diagnosis, which is expected to create significant demand for point of care diagnostics market. The market is expected to gain significant growth, owing to further developments in point-of-care diagnostics aimed towards impacting medical outcomes, increased adoption of rapid medical diagnostic devices, and rising prevalence of chronic diseases such as HIV, infectious diseases, and diabetes. Development of innovative point of care tests for wide number of applications is expected to fuel growth of the market.

Increasing launch and approval of novel product is supporting growth of the market

High product and test volumes are driving growth of the Point of care diagnostics market. Furthermore, leading market players are focused on launching novel products to expand their product portfolio for treatment of several diseases using advanced technologies. For instance, in February 2018, Siemens Healthineers received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Blood Urea Nitrogen (BUN) and Total Carbon Dioxide (TCO2) point-of-care tests, which is intended for use in the diagnosis of renal diseases and metabolic imbalances. Furthermore, in 2017, Beckman Coulter Diagnostics received CE Mark clearance for new high-sensitivity troponin assay, which aids in diagnosing myocardial infarction for patients presenting with chest pain or other ischemic symptoms.

Point of care diagnostic products are often subjected to recalls due to product issues, which may be technical or any other malfunctioning. For instance, Abbott Point of Care, Inc.’s product i-Stat PT/INR was recalled in 2015, due to result associated problems.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1515

Major players operating in the point of care diagnostics market include Danaher Corporation, Abbott Laboratories, Acon Laboratories, Inc., Hoffman-La Roche Ltd., Becton, Dickinson, and Company, Johnson & Johnson, Trinity Biotech Plc., and Siemens Healthineers.

Increasing prevalence of chronic diseases is expected to propel demand for diagnostic tests providing rapid results

According to the World Health Organization (WHO), in 2015, around 3, 23,000 new cases of TB and an estimated 32,000 deaths from tuberculosis were reported in the European region. Moreover, out of around 3, 23,000 people with TB cases in this region, 27,000 people were reported to be suffering from HIV co-infection. Incidences of chronic diseases such as cancer, diabetes, and cardiovascular conditions is increasing, which is expected to positively impact growth of the point of care diagnostics market. This is due to increasing demand from patients for rapid diagnosis and treatment. For instance, according to the World Health Organization (WHO), cancer was responsible for 8.8 million deaths in 2015, worldwide. Furthermore, according to American Diabetes Association (ADA), in 2015, around 30.3 million people in the U.S. were suffering from diabetes and around 1.5 million people are diagnosed with the disease annually. POC diagnostic tests aid in quick diagnosis and treatment initiation, therefore, the market is projected to witness high growth over the forecast period.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Biomarkers Market To Receive Overwhelming Hike In Revenues By 2026 Wed, 10 Apr 2019 08:11:24 +0200 http://comunicati.net/comunicati/aziende/varie/539944.html http://comunicati.net/comunicati/aziende/varie/539944.html Coherent Market Insights Coherent Market Insights The Biomarkers Market is estimated to be valued at US$ 29,518.2 Mn in 2017 and is expected to witness a robust CAGR of 13.6% during the forecast period (2017-2025).

Biomarkers are used for diagnosis and drug development, as these biomarkers can indicate diseases in the body. Furthermore, biomarkers can be any specific cells, molecules, genes or gene products, enzymes or hormones. Biomarker-based test are precise and rapid, which help in early prediction of susceptibility, prognosis, diagnosis, and treatment of disease. Hence, increasing research and development activities for identifying new biomarkers to diagnose or treat diseases is expected to be major factor growth of the market.

Biomarker are required for personalized medicine as it helps to identify the unique characteristics of the disease and helps to tailor medicine according to the need of patients. Hence, to cater to demand for personalized medicines, pharmaceutical companies are investing in R&D, which is expected to lead to identification of novel biomarkers, thus aiding in growth of the market.

Market Dynamics

The global biomarkers market is projected to witness significant growth over the forecast period, owing to rapid advancements in technology for development of novel biomarker. For instance, in February 2018, FDA granted marketing authorization to Banyan Biomarkers, Inc. for the first diagnostic blood test for traumatic brain injury named Banyan BTI. Such innovations, targeting different indications, is expected to drive biomarkers market growth in the near future.

Biomarkers are gaining significant traction in product development and treatment of disorders related to chromosome structure, Turner syndrome, Down syndrome, Patau syndrome, Edwards’s syndrome, and others, which is propelling demand for biomarkers. For instance, in February 2018, FDA granted marketing authorization to Banyan Biomarkers, Inc. for the first diagnostic blood test for traumatic brain injury, Banyan BTI. Therefore, introduction of such innovative diagnostic tools for various disease indication is projected to fuel growth of the biomarkers market over the forecast period.

Moreover, pharmaceutical companies have started outsourcing the complex bio analysis not only to cut down costs, however, to take advantage of specialized expertise to improve efficiency in drug development process. For instance, in March 2018, the SenzaGen signed a key license agreement with Burlesson Research Technologies, Inc., (BRT)—a contract research organization in the U.S., specializing in immunotoxicology. This agreement, will provide BRTs 'GARD' to a broader market.

Competitive Analysis

Key players are involved in new product launches to cater to increasing demand for biomarkers. For instance, in 2016 Abbott Laboratories launched Point-of-Care i-STAT Alinity, an innovative, handheld blood testing platform. Some of the other key players in biomarkers market include Medtronic plc, BG Medicine, Inc., F. Hoffmann-La Roche Ltd., Seimens Healthnineers, Nexus-DX, Qiagen N.V., and Lifesign LLC.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1530

Increasing demand for precision medicine to drive the growth of the global biomarkers market

North America accounts for the largest share in the global biomarkers market and this is attributed to adoption of precision medicine and growing prevalence of cancer in the region. According to the National Cancer Institute, 2016, it was estimated that 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from cancer disease. The number of people suffering from cancer is expected to rise to 19 million by 2024, which supports increasing demand for precision medicine.

Furthermore, the U.S. government in 2015 announced the launch of Precision Medicine Initiative that aimed to revolutionize the treatment to improve health, as precision medicine is an innovative approach to offer tailored treatment. Precision Medicine Initiative have led to development of novel drugs and new treatments, tailored for specific characteristic such as person’s genetic makeup or genetic profile of an individual tumor that helps to transform the way of treatment. This also favors growth of the biomarkers market in the near future. As for the development of precision medicine, it is essential to identify biomarkers.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>